<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02310243</url>
  </required_header>
  <id_info>
    <org_study_id>AMLSG 23-14</org_study_id>
    <nct_id>NCT02310243</nct_id>
  </id_info>
  <brief_title>Study of Palbociclib in MLL-rearranged Acute Leukemias</brief_title>
  <official_title>Phase Ib/IIa Study of Palbociclib in MLL-rearranged Acute Leukemias AMLSG 23-14/Palbo-AL-1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Tumor Diseases, Heidelberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Ulm</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diagnosis: Acute myeloid leukemia; Acute lymphoblastic leukemia Age ≥ 18 years, no upper age&#xD;
      limit Study drug: Palbociclib Phase Ib/IIa, open-label&#xD;
&#xD;
        -  Phase Ib: Based on previous experience with 125 mg palbociclib once daily for 21 days&#xD;
           followed by 7 days of rest in patients with breast cancer, liposarcoma, non-small cell&#xD;
           lung cancer, hepatocellular carcinoma, ovarian cancer, mantle-cell lymphoma, and&#xD;
           glioblastoma, this regimen will be chosen for the first dose to be evaluated in the&#xD;
           phase Ib. Based on a 3 + 3 modified Fibonacci design, the tolerable dose of palbociclib&#xD;
           for the phase IIa is defined.&#xD;
&#xD;
        -  Phase IIa: single-agent palbociclib using the tolerable dose defined in the phase Ib&#xD;
           part of the study is administered once daily for 21 days followed by 7 days of rest.&#xD;
           Based on the optimal two-stage design of Simon, 21 patients are treated in the first&#xD;
           stage. If results are positive, 29 additional patients will be recruited into the second&#xD;
           stage of the study. An efficacy of the investigational therapy will be rejected in the&#xD;
           first stage of 21 treated patients if two or less patients achieve complete remission&#xD;
           (CR), CR with incomplete blood count recovery (CRi), partial remission (PR), or&#xD;
           anti-leukemic effect (ALE). If three or more patients achieve CR, CRi, PR, or ALE during&#xD;
           this first stage, the trial is intended to be continued in the second stage with a total&#xD;
           sample size of 50 patients.&#xD;
&#xD;
      Start of recruitment: July 2015 End of recruitment: July 2017 End of study (last patient&#xD;
      out): July 2018 The treatment duration of an individual patient is estimated to be 2-6&#xD;
      months, but may be unlimited in patients with sustained response (&quot;case-by-case decision&quot;).&#xD;
&#xD;
      Observation time per patient after entry into the study (incl. treatment) is at least 12&#xD;
      months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>Safety assessments</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose of palbociclib</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>overall response rate</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival</measure>
    <time_frame>three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of target (CDK6) inhibition by palbociclib</measure>
    <time_frame>three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Quality of life</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Palbociclib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase1b: 125 mg palbociclib once daily for 21 days followed by 7 days of rest; this regimen will be chosen for the first dose to be evaluated.&#xD;
phase IIa: single-agent palbociclib using the tolerable dose defined in the phase Ib part of the study is administered once daily for 21 days followed by 7 days of rest.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib</intervention_name>
    <description>oral, once daily (125mg, 100mg or 75mg) for 21 days</description>
    <arm_group_label>Palbociclib</arm_group_label>
    <other_name>PD-0332991-00</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with confirmed diagnosis of acute leukemia with MLL rearrangement according&#xD;
             to the 2008 WHO Classification&#xD;
&#xD;
          -  Patients with MLL-rearranged leukemia who are refractory to standard induction therapy&#xD;
             and not immediate candidates for allogeneic HSCT (bridge to transplant is allowed)&#xD;
&#xD;
          -  Patients with MLL-rearranged leukemia who relapsed after standard first-line treatment&#xD;
             and are not immediate candidates for allogeneic HSCT (bridge to transplant is allowed)&#xD;
&#xD;
          -  Patients with newly diagnosed MLL-rearranged leukemia who are not eligible for&#xD;
             intensive first-line therapy&#xD;
&#xD;
          -  Genetic/histologic/immunohistologic assessment in one of the central laboratories&#xD;
&#xD;
          -  Age ≥ 18 years, no upper age limit&#xD;
&#xD;
          -  WHO performance status of ≤ 2&#xD;
&#xD;
          -  No prior chemotherapy two weeks before study entry except hydroxyurea to control&#xD;
             hyperleukocytosis&#xD;
&#xD;
          -  Non-pregnant and non-nursing. Women of child-bearing potential must have a negative&#xD;
             serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 72 hours&#xD;
             prior to registration (WOCBP is defined as a sexually active mature woman who has not&#xD;
             undergone a hysterectomy or who has had menses at any time in the preceding 24&#xD;
             months).&#xD;
&#xD;
          -  Female patients in the reproductive age and male patients must agree to avoid getting&#xD;
             pregnant or to father a child while on therapy and for three months after the last&#xD;
             dose of therapy.&#xD;
&#xD;
          -  Women of child-bearing potential must either commit to continued abstinence from&#xD;
             heterosexual intercourse or begin one acceptable method of birth control (IUD, tubal&#xD;
             ligation, or partner's vasectomy). Hormonal contraception is an inadequate method of&#xD;
             birth control.&#xD;
&#xD;
          -  Men must agree not to father a child and must use a latex condom during any sexual&#xD;
             contact with WOCBP while receiving therapy and for three months after therapy is&#xD;
             stopped, even if they have undergone successful vasectomy.&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with palbociclib&#xD;
&#xD;
          -  Performance status &gt; 2 according to WHO criteria&#xD;
&#xD;
          -  Organ insufficiency: creatinine &gt; 1.5 x upper normal serum level; bilirubin, AST, or&#xD;
             AP &gt; 2.5 x upper normal serum level; heart failure NYHA III/IV; uncontrolled&#xD;
             hypertension; unstable angina; serious cardiac arrhythmia; severe obstructive or&#xD;
             restrictive ventilation disorder&#xD;
&#xD;
          -  Uncontrolled infection&#xD;
&#xD;
          -  Patients with a &quot;currently active&quot; second malignancy other than non-melanoma skin&#xD;
             cancer. Patients are not considered to have a &quot;currently active&quot; malignancy if they&#xD;
             have completed therapy and are considered by their physician to be at less than 30%&#xD;
             risk of relapse within one year.&#xD;
&#xD;
          -  Severe neurologic or psychiatric disorder interfering with ability of giving informed&#xD;
             consent&#xD;
&#xD;
          -  Known or suspected active alcohol or drug abuse&#xD;
&#xD;
          -  Known positivity for HIV, active HAV, HBV, or HCV infection&#xD;
&#xD;
          -  Bleeding disorder unrelated to leukemia&#xD;
&#xD;
          -  Uncontrolled CNS involvement (treatment for CNS-involvement prior to inclusion is&#xD;
             allowed)&#xD;
&#xD;
          -  QTc &gt; 470 msec (based on the mean value of triplicate ECGs), family or personal&#xD;
             history of long or short QT syndrome, Brugada syndrome, or known history of QTc&#xD;
             prolongation or Torsade de Pointes&#xD;
&#xD;
          -  Uncontrolled electrolyte disorders that can aggravate the effects of a QTc-prolonging&#xD;
             drug (e.g., hypocalcemia, hypokalemia, hypomagnesemia)&#xD;
&#xD;
          -  No consent for registration, storage, and processing of individual disease&#xD;
             characteristics, information on the course of the disease, and information obtained&#xD;
             from the family physician and/or other physicians involved in the treatment of the&#xD;
             patient about study participation&#xD;
&#xD;
          -  No consent for biobanking&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Klinikum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Schmid, MD</last_name>
      <email>christoph.schmid@klinikum-augsburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Bad Saarow</name>
      <address>
        <city>Bad Saarow</city>
        <zip>15526</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Schöndube, MD</last_name>
      <email>daniel.schoendube@helios-kliniken.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Bladus, MD</last_name>
      <email>claudia.baldus@charite.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Neukölln</name>
      <address>
        <city>Berlin</city>
        <zip>12351</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maike de Wit, MD</last_name>
      <email>maike.dewit@vivantes.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité Campus Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jörg Westermann, MD</last_name>
      <email>joerg.westermann@charite.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin Tina Mayer, MD</last_name>
      <email>karin.mayer@ukb.uni-bonn.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Braunschweig gGmbH</name>
      <address>
        <city>Braunschweig</city>
        <zip>38114</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jürgen Krauter, MD</last_name>
      <email>krauter.juergen@mh-hannover.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Schroeder, MD</last_name>
      <email>thomas.schroeder@med.uni-duesseldorf.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kliniken Essen Süd, Ev. Krankenhaus Essen-Werden gGmbH</name>
      <address>
        <city>Essen</city>
        <zip>45239</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed Wattad, MD</last_name>
      <email>m.wattad@kliniken-essen-sued.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Malteser Krankenhaus St. Franziskus-Hospital</name>
      <address>
        <city>Flensburg</city>
        <zip>24939</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadezda Basara, MD</last_name>
      <email>nadezda.basara@malteser.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>791016</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralph Wäsch, MD</last_name>
      <email>ralph.waesch@uniklinik-freiburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MVZ Osthessen</name>
      <address>
        <city>Fulda</city>
        <zip>36043</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Distelrath, MD</last_name>
      <email>distelrath@mvz-osthessen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Giessen</name>
      <address>
        <city>Giessen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maisun Abu Samara, MD</last_name>
      <email>maisun.abu.samra@innere.med.uni-giessen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walter Fiedler, MD</last_name>
      <email>fiedler@uke.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Heuser, MD</last_name>
      <email>heuser.michael@mh-hannover.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alwin Krämer, MD</last_name>
      <email>Alwin.Kraemer@med.uni-heidelberg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Karlsruhe gGmbH</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Ringhoffer, MD</last_name>
      <email>mark.ringhoffer@klinikum-karlsruhe.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24116</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heinz-August Horst, MD</last_name>
      <email>h.horst@med2.uni-kiel.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Caritas-Krankenhaus Lebach</name>
      <address>
        <city>Lebach</city>
        <zip>66822</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Kremers, MD</last_name>
      <email>stephankremers@onkologie-lebach.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uni-Klinikum der Otto-von-Guericke-Universität</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Wolleschak, MD</last_name>
      <email>denise.wolleschak@med.ovgu.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Johannes Gutenberg-Universität</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Kindler, MD</last_name>
      <email>thomas.kindler@unimedizin-mainz.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pius Hospital Oldenburg</name>
      <address>
        <city>Oldenburg</city>
        <zip>26121</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Griesinger, MD</last_name>
      <email>frank.griesinger@pius-hospital.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitätsklinik Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helmut Salih, MD</last_name>
      <email>Helmut.Salih@med.uni-tuebingen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Paschka, MD</last_name>
      <phone>0049-731-500</phone>
      <phone_ext>45521</phone_ext>
      <email>peter.paschka@uniklinik-ulm.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>December 1, 2014</study_first_submitted>
  <study_first_submitted_qc>December 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2014</study_first_posted>
  <last_update_submitted>April 11, 2019</last_update_submitted>
  <last_update_submitted_qc>April 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Ulm</investigator_affiliation>
    <investigator_full_name>Peter Paschka</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>Acute myeloid leukemia</keyword>
  <keyword>Acute lymphoblastic leukemia</keyword>
  <keyword>MLL-rearranged leukemia</keyword>
  <keyword>Palbociclib (PD-0332991-00)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Palbociclib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

